Lexeo Therapeutics, Inc.(NASDAQ:LXEO) 
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t...
Website: https://www.lexeotx.com/
Founded: 2017
IPO Price: $11 (Nov 13, 2023)
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 2.53
H 2.68
L 2.27
C 2.33
V 542,944
10EMA 2.33
20EMA 2.33
60EMA 2.33
120EMA 2.33
250EMA 2.33